Hemofil M is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in people with factor VIII deficiency due to hemophilia A. The technical name of Hemofil M is Antihemophilic factor (human), method M, monoclonal purified.
Hemofil M is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.
How do I take it?
Prescribing information states that Hemofil M is given as an intravenous injection.
Hemofil M comes dried in single-use vials that must be reconstituted before injection.
The FDA-approved label for Hemofil M lists common side effects including fever, headache, dizziness, a strange taste in the mouth, and infusion site inflammation.
Serious side effects listed for Hemofil M include life-threatening hypersensitivity reactions and the development of inhibitors.
For more details about this treatment, visit:
Hemofil M prescribing information (PDF) - Shire
Treatment of Hemophilia - Hemophilia Federation of America